- IMGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $21.8 million.
- IMGN has traded 582,862 shares today.
- IMGN is down 3.2% today.
- IMGN was up 5.6% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in IMGN with the Ticky from Trade-Ideas. See the FREE profile for IMGN NOW at Trade-Ideas More details on IMGN: ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Currently there are 3 analysts that rate Immunogen a buy, 2 analysts rate it a sell, and 5 rate it a hold. The average volume for Immunogen has been 1.7 million shares per day over the past 30 days. Immunogen has a market cap of $507.0 million and is part of the health care sector and drugs industry. The stock has a beta of 1.84 and a short float of 14.4% with 2.41 days to cover. Shares are down 59.6% year-to-date as of the close of trading on Friday.